REFERENCES:

Boccardo F et al. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: Results of a multicentric Italian study. Ann Oncol 1994;5:337-342. Abstract

Bonneterre J et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast carcinoma. Results of two randomized trials designed for combined analysis. Cancer 2001;92:2247- 2258. Abstract

Bundred N et al. ICI 182,780 (fulvestrant) an estrogen receptor downregula-tor reduces cell turnover index more effectively than tamoxifen. Proc ASCO 2001; Abstract 1660.

Buzdar A et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001;19(14):3357-66. Abstract

Buzdar A et al. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer (ABC) in postmenopausal (PM) women? Combined analysis from two identically designed multicenter trials. Proc ASCO 2000; Abstract 609D.

Cheung KL et al. The combined use of goserelin and anastrozole as second-line endocrine therapy in premenopausal women with advanced breast cancer: A study of its clinical and endocrine effects. Proc ASCO 2001; Abstract 1937.

Curran M, Wiseman L. Fulvestrant. Drugs. 2001;61:807-13; discussion 814. Abstract

England GM, Jordan VC. Pure antiestrogens as a new therapy for breast cancer. Oncol Res 1997;9:397-402. Abstract

Erikstein B et al. ICI 182,780 (‘Faslodex’) 250 mg monthly intramuscular (i.m.) injection shows consistent pk profile when given as either 1 x 5ml or 2 x 2.5 ml injections in postmenopausal women with advanced breast cancer (ABC). Proc ASCO 2001; Abstract 2025.

Forward D et al. Combined use of goserelin (Zoladex)and anastrozole (Arimidex) in premenopausal women with metastatic breast cancer (MBC). Proc ASCO 2000; Abstract 582.

Gradishar WJ, Jordan VC. Clinical potential of new antiestrogens. J Clin Oncol 1997;15:840-52. Abstract

Howell A. Faslodex (ICI 182780). An oestrogen receptor downregulator. Eur J Cancer 2000;36 Suppl 4:S87-8. Abstract

Howell A et al. ICI 182,780 (Faslodex): Development of a novel, “pure” antiestrogen. Cancer 2000;89(4):817-825. Abstract

Howell A et al. Comparison of efficacy and tolerability of fulvestrant (Faslodex) with anastrozole (Arimidex) in post-menopausal women with advanced breast cancer. Breast Ca Res Treat 2000;64(1): No abstract available.

Jonat W et al. A randomised study to compare the effect of the luteinising hormone-releasing hormone (LH-RH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur J Cancer 1995;31:137-142. Abstract

Klijn JG et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH)agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol 2001;19:343-53. Abstract

Knoche AJ et al. Efficacy of anastrozole in a consecutive series of advanced breast cancer patients treated with multiple prior chemotherapies and endocrine agents: MD Anderson Cancer Center experience. Breast J 1999;5(3):176-181. Abstract

Lonning PE et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial. J Clin Oncol 2000;18(11):2234-44. Abstract

Michaud LB, Buzdar AU. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer. Drugs Aging 2000;16:261-71. Abstract

Mouridsen H et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19(10):2596-606. Abstract

Nabholtz JM et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. J Clin Oncol 2000;18(22):3758-3767. Abstract

Osborne CK et al. Selective estrogen receptor modulators: Structure, function, and clinical use. J Clin Oncol 2000;18(17):3172-3186. Abstract

Osborne CK. A Double-blind randomized trial comparing the efficacy and tolerability of Faslodex™ (fulvestrant) with Arimidex™ (anastrozole) in post-menopausal (PM) women with advanced breast cancer (ABC). Breast Ca Res Treat 2000;64(1): No abstract available.

Robertson JFR. A comparison of the single-dose pharmacokinetics (PK) of ‘Faslodex’ (fulvestrant) 250 mg when given as either a one x 5-ml intra-muscular (i.m.) injection or two x 2.5-ml injections in postmenopausal (PM) women with advanced breast cancer (ABC). Breast Ca Res Treat 2000; No abstract available

Robertson JFR et al. Duration of remission to ICI 182,780 compared to megestrol acetate in tamoxifen-resistant breast cancer. Breast 1997;6:186-9. No abstract available

Robertson JFR et al. The Pharmacokinetics of Single Dose Faslodex™ (ICI 182,780) in Postmenopausal Primary Breast Cancer - Relationship with Estrogen Receptor (ER) Down Regulation. Proc ASCO 2000; Abstract 362.

Thurlimann B et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: A phase II multicentre multinational study. Exemestane Study Group. Eur J Cancer 1997;33(11):1767-73. Abstract

Back | Top of Page